A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

References

• Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012; 30(17):2046-2054; PMID:22547592; https://doi.org/10.1200/JCO.2011.38.4032
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26):2443-2454; PMID:22658127; https://doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26):2455-2465; PMID:22658128; https://doi.org/10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192(7):1027-1034; PMID:11015443; https://doi.org/10.1084/jem.192.7.1027
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2(3):261-268; PMID:11224527; https://doi.org/10.1038/85330
   PubMed Web of Science ®Google Scholar
• Selenko-Gebauer N, Majdic O, Szekeres A, Hofler G, Guthann E, Korthauer U, Zlabinger G, Steinberger P, Pickl WF, Stockinger H, et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 2003; 170(7):3637-3644; PMID:12646628; https://doi.org/10.4049/jimmunol.170.7.3637
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8(8):793-800; PMID:12091876
   PubMed Web of Science ®Google Scholar
• Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004; 10(15):5094-5100; PMID:15297412; https://doi.org/10.1158/1078-0432.CCR-04-0428
   PubMed Web of Science ®Google Scholar
• Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014; 14(8):535-546; PMID:25056707; https://doi.org/10.1038/nrc3775
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66(4):271-289; PMID:27253694; https://doi.org/10.3322/caac.21349
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373(17):1627-1639; PMID:26412456; https://doi.org/10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Horn L, Borghaei H, Spigel DR, Steins M, Ready N, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol 2015; 33(18_suppl):LBA109; PMID:28147722; https://doi.org/10.1200/jco.2015.33.18_suppl.lba109
   PubMed Web of Science ®Google Scholar
• Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody-dependent cellular cytotoxicity activity of a novel Anti-PD-L1 antibody Avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 2015; 3(10):1148-1157; PMID:26014098; https://doi.org/10.1158/2326-6066.CIR-15-0059
   PubMed Web of Science ®Google Scholar
• Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJ, Leach J, Edenfield WJ, Wang D, Grote HJ, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol 2017; 18(5):599-610; PMID:28373005; https://doi.org/10.1016/S1470-2045(17)30240-1
   PubMed Web of Science ®Google Scholar
• Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marte JL, Lepone LM, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 2017; 18(5):587-598; PMID:28373007; https://doi.org/10.1016/S1470-2045(17)30239-5
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20(19):5064-5074; PMID:24714771; https://doi.org/10.1158/1078-0432.CCR-13-3271
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515(7528):568-571; PMID:25428505; https://doi.org/10.1038/nature13954
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515(7528):563-567; PMID:25428504; https://doi.org/10.1038/nature14011
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119(6):1420-1428; PMID:19487818; https://doi.org/10.1172/JCI39104
   PubMed Web of Science ®Google Scholar
• David JM, Dominguez C, Palena C. Pharmacological and immunological targeting of tumor mesenchymalization. Pharmacol Ther 2017; 170:212-225; PMID:27916651; https://doi.org/10.1016/j.pharmthera.2016.11.011
   PubMed Web of Science ®Google Scholar
• Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009; 15(3):195-206; PMID:19249678; https://doi.org/10.1016/j.ccr.2009.01.023
   PubMed Web of Science ®Google Scholar
• Akalay I, Janji B, Hasmim M, Noman MZ, Andre F, De Cremoux P, Bertheau P, Badoual C, Vielh P, Larsen AK, et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res 2013; 73(8):2418-2427; PMID:23436798; https://doi.org/10.1158/0008-5472.CAN-12-2432
   PubMed Web of Science ®Google Scholar
• Hamilton DH, Huang B, Fernando RI, Tsang KY, Palena C. WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition. Cancer Res 2014; 74(9):2510-2519; PMID:24626094; https://doi.org/10.1158/0008-5472.CAN-13-1894
   PubMed Web of Science ®Google Scholar
• Akalay I, Tan TZ, Kumar P, Janji B, Mami-Chouaib F, Charpy C, Vielh P, Larsen AK, Thiery JP, Sabbah M, et al. Targeting WNT1-inducible signaling pathway protein 2 alters human breast cancer cell susceptibility to specific lysis through regulation of KLF-4 and miR-7 expression. Oncogene 2015; 34(17):2261-2271; PMID:24931170; https://doi.org/10.1038/onc.2014.151
   PubMed Web of Science ®Google Scholar
• David JM, Hamilton DH, and Palena C. MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition. Oncoimmunology 2016; 5(4):e1117738; PMID:27141403; https://doi.org/10.1080/2162402X.2015.1117738
   PubMed Web of Science ®Google Scholar
• Goswami MT, Reka AK, Kurapati H, Kaza V, Chen J, Standiford TJ, Keshamouni VG. Regulation of complement-dependent cytotoxicity by TGF-beta-induced epithelial-mesenchymal transition. Oncogene 2016; 35(15):1888-1898; PMID:26148233; https://doi.org/10.1038/onc.2015.258
   PubMed Web of Science ®Google Scholar
• Kudo-Saito C, Shirako H, Ohike M, Tsukamoto N, Kawakami Y. CCL2 is critical for immunosuppression to promote cancer metastasis. Clin Exp Metastasis 2013; 30(4):393-405; PMID:23143679; https://doi.org/10.1007/s10585-012-9545-6
   PubMed Web of Science ®Google Scholar
• Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014; 5:5241; PMID:25348003; https://doi.org/10.1038/ncomms6241
   PubMed Web of Science ®Google Scholar
• Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M, Hiraki M, Maeda T, Hu X, Adeegbe D, et al. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene 2017; 36(28):4037-4046, Mar 13 [ Epub ahead of print]; PMID:28288138; https://doi.org/10.1038/onc.2017.47
   PubMed Web of Science ®Google Scholar
• Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M, Ghebeh H. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer 2015; 14:149; PMID:26245467; https://doi.org/10.1186/s12943-015-0421-2
   PubMed Web of Science ®Google Scholar
• Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A, Takiguchi Y. Drug resistance originating from a TGF-beta/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Int J Oncol 2016; 48(5):1825-1836; PMID:26984042; https://doi.org/10.3892/ijo.2016.3419
   PubMed Web of Science ®Google Scholar
• Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, et al. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res 2016; 22(14):3630-3642; PMID:26851185; https://doi.org/10.1158/1078-0432.CCR-15-1434
   PubMed Web of Science ®Google Scholar
• Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 2013; 13(11):788-799; PMID:24132110; https://doi.org/10.1038/nrc3603
   PubMed Web of Science ®Google Scholar
• Strauss J, Heery CR, Schlom J, Madan RA, Lamping E, Marte J, Cordes L, Lan Y, Mahnke L, Helwig C, et al. A phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors (abstr). TGF-ß Immunity Inflammation Cancer Keystone Symposia. Mol Cell Biol 2017
   Google Scholar
• Gulley JL, Heery CR, Schlom J, Madan RA, Cao L, Lamping E, Marte JL, Cordes LM, Christensen O, Helwig C, et al. Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors. J Clin Oncol 2017; 35:15_suppl, 3006-3006. https://doi.org/10.1200/JCO.2017.35.15_suppl.3006
   Google Scholar
• Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003; 4(8):657-665; PMID:12923528; https://doi.org/10.1038/nrm1175
   PubMed Web of Science ®Google Scholar
• Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst 2016; 108(1); pii:djv303; PMID:26577528; https://doi.org/10.1093/jnci/djv303
   PubMedGoogle Scholar
• Zhao L, Yu H, Yi S, Peng X, Su P, Xiao Z, Liu R, Tang A, Li X, Liu F, et al. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget 2016; 7(29):45370-45384; PMID:27248318; https://doi.org/10.18632/oncotarget.9659
   PubMed Web of Science ®Google Scholar
• Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem 2007; 101(1):9-33; PMID:17340614; https://doi.org/10.1002/jcb.21255
   PubMed Web of Science ®Google Scholar
• Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, Oh S, Shin JG, Yao S, Chen L, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006; 580(3):755-762; PMID:16413538; https://doi.org/10.1016/j.febslet.2005.12.093
   PubMed Web of Science ®Google Scholar
• Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res 2016; 22(3):609-620; PMID:26420858; https://doi.org/10.1158/1078-0432.CCR-15-0876
   PubMed Web of Science ®Google Scholar
• Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim JH, Jeon YK, Lee JS, Kwon SK, Hah JH, et al. PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget 2016; 7(13):15901-15914; PMID:26893364; https://doi.org/10.18632/oncotarget.7431
   PubMed Web of Science ®Google Scholar
• Kim S, Koh J, Kim MY, Kwon D, Go H, Kim YA, Jeon YK, Chung DH. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Hum Pathol 2016; 58:7-14; PMID:27473266; https://doi.org/10.1016/j.humpath.2016.07.007
   PubMed Web of Science ®Google Scholar
• Shimoji M, Shimizu S, Sato K, Suda K, Kobayashi Y, Tomizawa K, Takemoto T, Mitsudomi T. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). Lung Cancer 2016; 98:69-75; PMID:27393509; https://doi.org/10.1016/j.lungcan.2016.04.021
   PubMed Web of Science ®Google Scholar
• Ni XY, Sui HX, Liu Y, Ke SZ, Wang YN, Gao FG. TGF-beta of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncol Rep 2012; 28(2):615-621; PMID:22614805; https://doi.org/10.3892/or.2012.1822
   PubMed Web of Science ®Google Scholar
• Song S, Yuan P, Wu H, Chen J, Fu J, Li P, Lu J, Wei W. Dendritic cells with an increased PD-L1 by TGF-beta induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells. Int Immunopharmacol 2014; 20(1):117-123; PMID:24606770; https://doi.org/10.1016/j.intimp.2014.02.027
   PubMed Web of Science ®Google Scholar
• Baas M, Besancon A, Goncalves T, Valette F, Yagita H, Sawitzki B, Volk HD, Waeckel-Enee E, Rocha B, Chatenoud L, et al. TGFbeta-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance. Elife 2016; 5:e08133; PMID:26824266; https://doi.org/10.7554/eLife.08133
   PubMed Web of Science ®Google Scholar
• Starke A, Wuthrich RP, and Waeckerle-Men Y. TGF-beta treatment modulates PD-L1 and CD40 expression in proximal renal tubular epithelial cells and enhances CD8 cytotoxic T-cell responses. Nephron Exp Nephrol 2007; 107(1):e22-29; PMID:17671397; https://doi.org/10.1159/000106506
   PubMedGoogle Scholar
• Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011; 22(10):1686-1698; PMID:21411626; https://doi.org/10.1091/mbc.E11-02-0103
   PubMed Web of Science ®Google Scholar
• Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, Gotz U, Hermeking H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011; 10(24):4256-4271; PMID:22134354; https://doi.org/10.4161/cc.10.24.18552
   PubMed Web of Science ®Google Scholar
• Liu X, Wang C, Chen Z, Jin Y, Wang Y, Kolokythas A, Dai Y, Zhou X. MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 2011; 440(1):23-31; PMID:21770894; https://doi.org/10.1042/BJ20111006
   PubMed Web of Science ®Google Scholar
• Miguez DG, Gil-Guinon E, Pons S, Marti E. Smad2 and Smad3 cooperate and antagonize simultaneously in vertebrate neurogenesis. J Cell Sci 2013; 126(Pt 23):5335-5343; PMID:24105267; https://doi.org/10.1242/jcs.130435
   PubMed Web of Science ®Google Scholar
• Liu L, Liu X, Ren X, Tian Y, Chen Z, Xu X, Du Y, Jiang C, Fang Y, Liu Z, et al. Smad2 and Smad3 have differential sensitivity in relaying TGFbeta signaling and inversely regulate early lineage specification. Sci Rep 2016; 6:21602; PMID:26905010; https://doi.org/10.1038/srep21602
   PubMed Web of Science ®Google Scholar
• Park BV, Freeman ZT, Ghasemzadeh A, Chattergoon MA, Rutebemberwa A, Steigner J, Winter ME, Huynh TV, Sebald SM, Lee SJ, et al. TGFbeta1-mediated SMAD3 enhances PD-1 expression on Antigen-Specific T cells in cancer. Cancer Discov 2016; 6(12):1366-1381; PMID:27683557; https://doi.org/10.1158/2159-8290.CD-15-1347
   PubMed Web of Science ®Google Scholar
• Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3(12):1355-1363; PMID:24078774; https://doi.org/10.1158/2159-8290.CD-13-0310
   PubMed Web of Science ®Google Scholar
• Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29(34):4741-4751; PMID:20531305; https://doi.org/10.1038/onc.2010.215
   PubMed Web of Science ®Google Scholar
• Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH, Palena C. An autocrine loop between TGF-beta1 and the transcription factor brachyury controls the transition of human carcinoma cells into a mesenchymal phenotype. Mol Cancer Ther 2013; 12(9):1805-1815; PMID:23783250; https://doi.org/10.1158/1535-7163.MCT-12-1007
   PubMed Web of Science ®Google Scholar
• Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 2015; 9:4479-4499; PMID:26309397; https://doi.org/10.2147/DDDT.S86621
   PubMed Web of Science ®Google Scholar
• Scognamiglio G, De Chiara A, Di Bonito M, Tatangelo F, Losito NS, Anniciello A, De Cecio R, D'Alterio C, Scala S, Cantile M, et al. Variability in immunohistochemical detection of programmed death ligand 1 (PD-L1) in cancer tissue types. Int J Mol Sci 2016; 17(5); pii:E790; PMID:27213372; https://doi.org/10.3390/ijms17050790
   PubMed Web of Science ®Google Scholar